1110P COVID-19 pandemic impact on healthcare professionals treating patients with neuroendocrine tumors (NET): An international NET CONNECT survey

por Hernando, J., Lamarca, A., Cives, M., Caplin, M.E., Pavel, M.E.
Publicado 2021

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

por Zaknun, John J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., Kwekkeboom, D. J.
Publicado 2013

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

por Bodei, L., Mueller-Brand, J., Baum, R. P., Pavel, M. E., Hörsch, D., O’Dorisio, M. S., O’Dorisio, T. M., Howe, J. R., Cremonesi, M., Kwekkeboom, D. J., Zaknun, J. J.
Publicado 2013